Essex Bio-Technology Announces 2022 Annual Financial Results

HONG KONG, Mar 8, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.Financial PerformanceDuring the year under review, the financial results of the Group, have been negatively impacted and ongoing clinical trial programmes have been delayed due to disruptions resulted from sporadic...

Related Keywords

Serbia ,Latvia ,Kazakhstan ,Australia ,Kyrgyzstan ,United States ,United Kingdom ,Yadian ,Tianjin ,China ,Armenia ,Belarus ,Czech Republic ,Indonesia ,Russia ,Hungary ,Singapore ,Poland ,Spain ,Chinese ,Shelly Cheng ,Patrick Ngiam ,Angela Shen ,Yan Li ,Essex Bio ,Zhuhai Essex Bio ,June Tuo ,Development License Agreement ,Significant Business Development Activities ,Technology Ltd Essex ,Shanghai Henlius Biotech Inc ,Strategic Financial Relations Limited Website ,Yesdok Pte Ltd ,European Union ,European Medicines Agency ,Group Beifushu ,National Medical Products Administration ,Market Development Entrenched Access Capability ,Therapeutic Goods Administration ,Bio Technology Ltd ,Stock Code ,Tobramycin Eye Drops ,Levofloxacin Eye Drops ,Sodium Hyaluronate Eye Drops ,Iodized Lecithin Capsules ,Marketing Authorisation Holder ,Exclusive Global Rights ,Know How Licence ,Patent Assignment Deed ,Know How Licence Agreement ,Shanghai Henlius Biotech ,Co Development License Agreement ,Best Under ,China Excellent ,Best Shareholder Relationship Award ,Zhuhai Essex Bio Pharmaceutical Company Limited ,Southeast Asian ,Results Announcement ,Bio Technology Limited ,Financial Relations Limited ,